NCT00294619已完成3 期
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.
LG Life Sciences1 个研究点 分布在 1 个国家目标入组 147 人开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- Changes in Fat Mass at the end of 26-week treatment from baseline
研究概览
简要总结
The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 23 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of at least 23 years and not more than 70 years of age
- •GHD of either adult onset(AO)or Childhood onset(CO), either idiopathic or secondary to pituitary disease
- •Confirmed diagnosis of GHD defined
- •IGF-1 SDS ≤ -1 at screening
- •No exposure to rhGH within the last 6 months
- •Patients with adequate adrenal function, which is confirmed by ACTH stimulation test at screening; or Patients with known secondary hypoadrenalism on adequate glucocorticoid replacement therapy
- •If applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 3 months before study entry
- •Women of child-bearing potential to be using a reliable method of contraception at the screening and be willing to use it throughout the study
- •A negative serum pregnancy test is required at screening for females of child-bearing potential.
排除标准
- •History of malignancy other than cranial tumor or leukemia causing GHD or fully treated basal cell carcinoma
- •Evidence of active malignancy
- •Evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months, or patients without MRI or CT data to confirm the tumor stability within the last 12 months
- •Significant hepatic dysfunction
- •Chronic renal impairment
- •Clinically significant pulmonary, cardiac, hepatic, renal, or neuromuscular disease
- •Prader-Willi syndrome
- •Acute severe illness in the last 6 months
- •Benign intracranial hypertension
- •Active Cushing's syndrome within the last 12 months
- •Uncontrolled hypertension
- •Patients with overt diabetes mellitus or evidence of persistent impaired glucose tolerance
- •Severe psychiatric disease or patients who cannot understand the objective and methods of the study or patients with current alcohol abuse
- •Pregnancy or lactation
- •Known hypersensitivity to any ingredient of the study drug
- •Inability to undergo scanning by dual-energy X ray absorptiometry (DXA) due to a body weight more than 130 kg or in situ internal or external devices known to interfere with DXA scanning
- •Weight reducing drugs or appetite suppressants
- •Anabolic steroids other than gonadal steroid replacement therapy within 2 months before study entry
- •Methylphenidate within 2 months before study entry
- •Systemic corticosteroids other than in replacement doses within the 3 months before study entry.
- •History of non-compliance with medications, un-cooperativeness or drug abuse
- •Patients participating in another study parallel to, or within 6 months prior to study entry, or previous participation in this study
- •Patients who are not able to comply with the study protocol for any reason.
研究组 & 干预措施
LB03002
Experimental
干预措施: growth hormone (Drug)
Placebo
Placebo Comparator
干预措施: growth hormone (Drug)
结局指标
主要结局
Changes in Fat Mass at the end of 26-week treatment from baseline
时间窗: 26 weeks
次要结局
- Changes in the following parameters at the end of 26-week treatment from baseline; other body composition parameters, QoL Score, Serum IGF-I, IGFBP-3 levels & SDS, Lipid profile, waist-to-hip ratio(26 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)Graft Versus Host DiseaseNCT00366145Mesoblast, Inc.260
招募中
3 期
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNeutropeniaNCT06056297X4 Pharmaceuticals176
已完成
3 期
Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in AdultsInfluenzaNCT00333398National Institute of Allergy and Infectious Diseases (NIAID)1,359
已完成
3 期
Flexible-Dose Trial in Early Parkinson's Disease (PD)Parkinson DiseaseNCT04223193AbbVie304
已完成
3 期
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyMigraineNCT02614196Eli Lilly and Company986